Bayer's Q1 2026 Financial Overview: Growth in Crop Science and Consumer Health Amidst Litigation
Bayer Aktiengesellschaft has released its financial outcomes for the first quarter of 2026, demonstrating resilience and strategic progress. The company achieved growth primarily driven by its Crop Science and Consumer Health divisions, which successfully counterbalanced the static performance of its Pharmaceuticals segment and considerable expenses incurred from ongoing litigation. Despite these challenges, Bayer remains committed to its financial outlook for 2026, emphasizing disciplined investment and operational efficiency.
The first quarter saw Bayer navigate a complex financial landscape, with its core businesses showing strength and adaptability. Crop Science, in particular, benefited from a significant influx of licensing revenue, bolstering overall sales. Concurrently, the Consumer Health sector experienced broad-based expansion across its various categories. While the Pharmaceuticals division maintained steady sales, the company's free cash flow was notably impacted by substantial litigation-related payments, reflecting a critical period for resolving legal issues. Leadership underscored their focus on managing these legal challenges while advancing strategic initiatives and maintaining a clear vision for future growth.
Growth Drivers and Strategic Investments
In the initial quarter of 2026, Bayer's financial results were largely propelled by strong performances in its Crop Science and Consumer Health segments. The Crop Science division recorded a significant increase in sales, partly due to an approximate EUR 450 million from soy licensing resolution revenue. Excluding this, the core agricultural business still showed a 1.4% growth, primarily driven by strong corn sales, despite an anticipated dip in crop protection products. The division's EBITDA margin stood impressively at about 40%, benefiting from higher-margin sales and operational efficiencies. Furthermore, Bayer is strategically expanding its product offerings, with plans to introduce the Plenexos insecticide to U.S. farmers, contingent on regulatory clarity and a favorable U.S. Supreme Court ruling on pesticide labeling.
The Consumer Health segment also contributed positively, achieving a 5% increase in sales across nearly all product categories. Notably, Dermatology and Nutritionals experienced double-digit growth, with e-commerce playing a pivotal role in boosting Nutritional sales. Despite challenging market conditions in key regions like the U.S. and China, the division maintained a healthy EBITDA margin of 22.6%. The Pharmaceuticals division, though stable, saw momentum from newer medicines like Nubeqa and KERENDIA compensating for declines in older products such as Xarelto and Eylea, holding an EBITDA margin of 29.2%. Bayer is also strategically investing in its pharmaceutical pipeline, highlighted by the acquisition of Perfuse Therapeutics, which aims to strengthen its ophthalmology presence with a focus on innovative treatments for glaucoma and diabetic retinopathy.
Financial Performance, Litigation, and Future Outlook
Bayer's first-quarter 2026 financial report revealed group sales of approximately EUR 13.4 billion, a 4% increase on a currency- and portfolio-adjusted basis. Core earnings per share rose to EUR 2.71. However, free cash flow was negative EUR 2.3 billion, largely due to around EUR 2 billion in payouts for PCB and glyphosate settlement activities, which was an expected outcome for the quarter. EBITDA before special items climbed 9% to EUR 4.5 billion, primarily driven by Crop Science. The company also experienced foreign exchange headwinds, totaling about EUR 890 million on the top line and EUR 320 million on the bottom line, mainly due to the U.S. dollar's strength. Net financial debt increased to EUR 32.5 billion, reflecting the negative cash flow, but still showed a year-over-year reduction of EUR 1.7 billion.
Litigation remains a significant focus for Bayer, with the company in a "crucial phase" of containment efforts. The class settlement agreement announced in February is progressing, with a final approval hearing scheduled for July. The ongoing U.S. Supreme Court case regarding federal preemption and pesticide labeling is also a key area of attention, with Bayer preparing for various outcomes through its multi-pronged legal strategy. On the restructuring front, approximately 14,000 jobs have been reduced as part of an organizational change to flatten hierarchies. Despite the financial implications of past acquisitions, particularly Monsanto, management reiterated its commitment to the 2026 guidance at constant currencies, emphasizing that the company is on track to meet its full-year targets across all businesses, while continuously monitoring geopolitical and foreign exchange risks.
